Monoclonal Gammopathy of Undetermined Significance (MGUS) Diagnosis and Management

Diagnostic Classification

A serum M-spike of 0.8g/dl falls within the diagnostic criteria for MGUS, which requires a serum monoclonal protein <3g/dl and bone marrow plasma cells <10%, according to the International Myeloma Society 1, 3
This level is well below the threshold of 3g/dl that would be consistent with smoldering multiple myeloma (SMM) or symptomatic multiple myeloma (MM), as defined by the International Myeloma Society 1, 3

The risk of progression from MGUS to multiple myeloma or related disorders depends on several factors, including M-protein size, with an M-spike of 0.8g/dl carrying a moderate risk of progression, according to the American Society of Clinical Oncology 5, 2
The risk is higher if the M-protein is IgA or IgM rather than IgG, as reported by the American Society of Hematology 2
An abnormal serum free light chain (FLC) ratio significantly increases progression risk, as stated by the International Myeloma Society 2
Higher bone marrow plasma cell percentages (>5%) are associated with increased risk, according to the American Society of Clinical Oncology 2

An M-spike of 0.8g/dl without end-organ damage does not require treatment, as recommended by the National Comprehensive Cancer Network (NCCN) 6, 3
This level represents stable disease if unchanged from previous measurements, according to the NCCN 6, 7
If this is a new finding, evaluation for potential CRAB features (hypercalcemia, renal dysfunction, anemia, bone lesions) is essential to rule out symptomatic multiple myeloma, as recommended by the NCCN 3, 7

Regular monitoring of the M-spike level is recommended to detect progression, as suggested by the American Society of Clinical Oncology 5, 2
For MGUS with an M-spike of 0.8g/dl, follow-up should include serum protein electrophoresis every 6-12 months, assessment of free light chain ratios, and clinical evaluation for development of CRAB features, as recommended by the International Myeloma Society 5, 2, 3, 7

Increase in M-spike by ≥0.5g/dl from the lowest confirmed value should raise suspicion for progression to multiple myeloma, as stated by the NCCN 6, 7
Development of CRAB features (hypercalcemia, renal insufficiency, anemia, bone lesions) or increase in bone marrow plasma cells to ≥10% should also prompt suspicion of progression, according to the International Myeloma Society 6, 7, 1, 3